LDLR and inflammatory bowel disease: Specifically, we found that lipid-lowering drug targets, such as ANGPTL3, APOC3, LPL, and LDLR, were closely associated with IBD risk, and their effects might be mediated indirectly through the modulation of specific gut microbiota (e.g., Lachnospiraceae FCS020 genus, Clostridium sensu stricto 1, Lentisphaeria class, Victivallales order, Lentisphaerae phylum, and Ruminococcaceae UCG009 genus) or immune factors (e.g., MIP-1β, IL-18, IL-12ra).